ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bind Therapeutics files for bankruptcy

by Rick Mullin
May 9, 2016 | APPEARED IN VOLUME 94, ISSUE 19

Bind Therapeutics, an oncology nanomedicine drug discovery company, and its affiliate Bind Biosciences Security Corp., have filed a reorganization petition in the U.S. Bankruptcy Court for the District of Delaware. CEO Andrew Hirsch says the filing will give the firm time to reorganize while continuing collaborations with Pfizer and AstraZeneca. Financial backers for the firm include David H. Koch’s DHK Investment and Polaris Partners.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment